News
GTBP
0.2960
-0.47%
-0.0014
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan
TipRanks · 1d ago
GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate
Benzinga · 1d ago
GT Biopharma reports Q2 results
Seeking Alpha · 1d ago
*GT Biopharma 2Q Research and Development Expenses About $1.1M >GTBP
Dow Jones · 1d ago
Weekly Report: what happened at GTBP last week (0803-0807)?
Weekly Report · 5d ago
Weekly Report: what happened at GTBP last week (0727-0731)?
Weekly Report · 08/03 09:09
Weekly Report: what happened at GTBP last week (0720-0724)?
Weekly Report · 07/27 09:10
Weekly Report: what happened at GTBP last week (0713-0717)?
Weekly Report · 07/20 09:09
Weekly Report: what happened at GTBP last week (0706-0710)?
Weekly Report · 07/13 09:10
Weekly Report: what happened at GTBP last week (0629-0703)?
Weekly Report · 07/06 09:10
Weekly Report: what happened at GTBP last week (0622-0626)?
Weekly Report · 06/29 09:09
Weekly Report: what happened at GTBP last week (0615-0619)?
Weekly Report · 06/22 09:11
Weekly Report: what happened at GTBP last week (0608-0612)?
Weekly Report · 06/15 09:11
GT Biopharma Lowers Stockholder Quorum to One-Third
TipRanks · 06/12 23:02
Weekly Report: what happened at GTBP last week (0601-0605)?
Weekly Report · 06/08 09:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/01 12:06
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
Benzinga · 06/01 11:31
Weekly Report: what happened at GTBP last week (0525-0529)?
Weekly Report · 06/01 09:11
The $13 Million Company Teaching the Immune System to Hunt Cancer
Barchart · 05/29 08:00
Weekly Report: what happened at GTBP last week (0518-0522)?
Weekly Report · 05/25 09:11
More
Webull provides a variety of real-time GTBP stock news. You can receive the latest news about Gt Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.